A proposed service plan for Binswanger Philippines, Inc. (International Property Consultants)

This service plan focuses on the development of the real estate brokerage division of Binswanger Philippines, Inc. specifically in terms of its services and marketing efforts. In line with this endeavor, the researchers aim to help the company be a premier real estate organization, through specific service development and marketing programs recommended. The real estate industry is a broad and volatile arena which is significantly affected by political and social factors. With this perspective at hand, Binswanger Philippines, Inc. strives to develop a competitive niche in the market, which includes major multinational real estate companies and freelance brokers/agents as well. Taking into consideration the different aspects in the industry and the current situation of the company, the researchers suggested the implementation of a more detailed service development and marketing programs. The former specifically involves the addition of members in the real estimate brokerage division, the development of its overall service through the activation of other functions, and the standardization of its computer database. The latter aims to increase the awareness level of its target market through seminars and advertisements. Both service and marketing development programs are intertwined to help the real estate brokerage team attain a better internal (within the organization) and external (reach market) position. Furthermore, this plan also aims to expand the market of the company in terms target person and location, through suggested special medium term and long-term special programs. In line with these objectives and recommended strategies, the profitability estimate projects the increase of net income by 27% after the implementation of the service plan. This realistic and conservative financial projection hopes to assist the real estate brokerage division contribute a significant contribution to the earnings of the whole company. Moreover, a consistent monitoring and evaluation of results would be implemented through the cautions determination of weaknesses and improving thereon. Through the team\u27s consistent and efficient work towards specified goals and objectives and the proper implementation of strategies, better results would be achieved

Improving Hand-Hygiene in 4 Clarke

https://scholarlycommons.baptisthealth.net/cohort-5-ebp-showcase/1003/thumbnail.jp

A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer.

Pancreatic cancer is one of the deadliest diseases in human malignancies. Among total pancreatic cancer patients, ~10% of patients are categorized as familial pancreatic cancer (FPC) patients, carrying germline mutations of the genes involved in DNA repair pathways (e.g., BRCA2). Personalized medicine approaches tailored toward patients mutations would improve patients outcome. To identify novel vulnerabilities of BRCA2-deficient pancreatic cancer, we generated isogenic Brca2-deficient murine pancreatic cancer cell lines and performed high-throughput drug screens. High-throughput drug screening revealed that Brca2-deficient cells are sensitive to Bromodomain and Extraterminal Motif (BET) inhibitors, suggesting that BET inhibition might be a potential therapeutic approach. We found that BRCA2 deficiency increased autophagic flux, which was further enhanced by BET inhibition in Brca2-deficient pancreatic cancer cells, resulting in autophagy-dependent cell death. Our data suggests that BET inhibition can be a novel therapeutic strategy for BRCA2-deficient pancreatic cancer

A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer

Abstract Pancreatic cancer is one of the deadliest diseases in human malignancies. Among total pancreatic cancer patients, ~10% of patients are categorized as familial pancreatic cancer (FPC) patients, carrying germline mutations of the genes involved in DNA repair pathways (e.g., BRCA2). Personalized medicine approaches tailored toward patients’ mutations would improve patients’ outcome. To identify novel vulnerabilities of BRCA2-deficient pancreatic cancer, we generated isogenic Brca2-deficient murine pancreatic cancer cell lines and performed high-throughput drug screens. High-throughput drug screening revealed that Brca2-deficient cells are sensitive to Bromodomain and Extraterminal Motif (BET) inhibitors, suggesting that BET inhibition might be a potential therapeutic approach. We found that BRCA2 deficiency increased autophagic flux, which was further enhanced by BET inhibition in Brca2-deficient pancreatic cancer cells, resulting in autophagy-dependent cell death. Our data suggests that BET inhibition can be a novel therapeutic strategy for BRCA2-deficient pancreatic cancer

Physics Briefing Book: Input for the European Strategy for Particle Physics Update 2020

The European Particle Physics Strategy Update (EPPSU) process takes a bottom-up approach, whereby the community is first invited to submit proposals (also called inputs) for projects that it would like to see realised in the near-term, mid-term and longer-term future. National inputs as well as inputs from National Laboratories are also an important element of the process. All these inputs are then reviewed by the Physics Preparatory Group (PPG), whose role is to organize a Symposium around the submitted ideas and to prepare a community discussion on the importance and merits of the various proposals. The results of these discussions are then concisely summarised in this Briefing Book, prepared by the Conveners, assisted by Scientific Secretaries, and with further contributions provided by the Contributors listed on the title page. This constitutes the basis for the considerations of the European Strategy Group (ESG), consisting of scientific delegates from CERN Member States, Associate Member States, directors of major European laboratories, representatives of various European organizations as well as invitees from outside the European Community. The ESG has the mission to formulate the European Strategy Update for the consideration and approval of the CERN Council

Physics Briefing Book: Input for the European Strategy for Particle Physics Update 2020

The European Particle Physics Strategy Update (EPPSU) process takes a bottom-up approach, whereby the community is first invited to submit proposals (also called inputs) for projects that it would like to see realised in the near-term, mid-term and longer-term future. National inputs as well as inputs from National Laboratories are also an important element of the process. All these inputs are then reviewed by the Physics Preparatory Group (PPG), whose role is to organize a Symposium around the submitted ideas and to prepare a community discussion on the importance and merits of the various proposals. The results of these discussions are then concisely summarised in this Briefing Book, prepared by the Conveners, assisted by Scientific Secretaries, and with further contributions provided by the Contributors listed on the title page. This constitutes the basis for the considerations of the European Strategy Group (ESG), consisting of scientific delegates from CERN Member States, Associate Member States, directors of major European laboratories, representatives of various European organizations as well as invitees from outside the European Community. The ESG has the mission to formulate the European Strategy Update for the consideration and approval of the CERN Council

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health